The Evolving Role of Adjuvant Immunotherapy in RCC
Dr. Susan Slovin examines how pembrolizumab has reshaped adjuvant therapy for renal cell carcinoma and outlines emerging strategies for biomarker-driven care.
Read More
Select Page
Susan F. Slovin, MD, PhD is a Genitourinary Medical Oncologist and Cellular Therapist, and the Associate Vice Chair of Academic Affairs for the Department of Medicine for the Memorial Sloan Kettering Cancer Institute in New York City, New York. Dr. Slovin specializes in prostate cancer, genitourinary cancers, cellular therapy, and clinical trials. Her clinical expertise is in clinical immunology, other genitourinary malignancies, internal medicine, and medical oncology.
Dr. Slovin earned her medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. She completed a residency in Internal Medicine at Mount Sinai Hospital in New York, New York. Dr. Slovin then completed a fellowship in Clinical Immunology at Scripps Clinic & Research Foundation in La Jolla, California. She completed a fellowship in Medical Oncology/Hematology at Memorial Sloan Kettering Cancer Center in New York, New York. Dr. Slovin then completed a fellowship in Medicine at Weill Cornell Medical College in [New York, New York.
Dr. Slovin has won numerous awards in recognition for her contributions to the field, including America’s Top Doctor (2025, 2024, 2023), Exceptional Women in Medicine (2024, 2023), and the Top Doctor New York Metro Area (2023). She has published 222 articles and book chapters in her field and has been featured in the Journal of Clinical Oncology, European Urology Oncology, and the Journal of Immunotherapy and Precision Oncology.
Susan F. Slovin, MD, PhD | Mar 2026
Dr. Susan Slovin examines how pembrolizumab has reshaped adjuvant therapy for renal cell carcinoma and outlines emerging strategies for biomarker-driven care.
Read More